For this, we examined expression of ER and HER2 proteins, two known clinical breast cancer biomarkers defining the HR+ and the HER2-E subtypes, respectively, as well as several other markers defining various breast cancer differentiation states including luminal, epithelial, basal, and mesenchymal phenotypes. The gene discussed is ERBB2; the disease is breast cancer.